NZ536787A - Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol - Google Patents
Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diolInfo
- Publication number
- NZ536787A NZ536787A NZ536787A NZ53678799A NZ536787A NZ 536787 A NZ536787 A NZ 536787A NZ 536787 A NZ536787 A NZ 536787A NZ 53678799 A NZ53678799 A NZ 53678799A NZ 536787 A NZ536787 A NZ 536787A
- Authority
- NZ
- New Zealand
- Prior art keywords
- androst
- ene
- diol
- prodrug
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 title 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 abstract 1
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 231100000863 loss of memory Toxicity 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229950009829 prasterone sulfate Drugs 0.000 abstract 1
- 230000036620 skin dryness Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9628698A | 1998-06-11 | 1998-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ536787A true NZ536787A (en) | 2006-03-31 |
Family
ID=22256669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ536787A NZ536787A (en) | 1998-06-11 | 1999-06-10 | Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol |
Country Status (22)
| Country | Link |
|---|---|
| US (12) | US6432940B1 (enExample) |
| EP (2) | EP1731157A3 (enExample) |
| JP (1) | JP2002517432A (enExample) |
| KR (3) | KR100679735B1 (enExample) |
| CN (3) | CN1243550C (enExample) |
| AR (1) | AR018660A1 (enExample) |
| AU (1) | AU4127499A (enExample) |
| BR (1) | BR9911115A (enExample) |
| CA (1) | CA2334702C (enExample) |
| HU (1) | HUP0102483A3 (enExample) |
| ID (1) | ID27922A (enExample) |
| IL (2) | IL140225A0 (enExample) |
| MX (1) | MXPA00012304A (enExample) |
| MY (1) | MY131522A (enExample) |
| NO (1) | NO20006286L (enExample) |
| NZ (1) | NZ536787A (enExample) |
| PL (1) | PL345955A1 (enExample) |
| RU (1) | RU2221569C2 (enExample) |
| TR (2) | TR200102867T2 (enExample) |
| TW (2) | TWI283579B (enExample) |
| WO (1) | WO1999063973A2 (enExample) |
| ZA (1) | ZA200007299B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200102867T2 (enExample) * | 1998-06-11 | 2002-06-21 | Endorecherchel@Inc | |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20060079492A1 (en) * | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
| CN1220491C (zh) | 1999-06-11 | 2005-09-28 | 沃特森药物公司 | 非口服雄激素类固醇用于制备改善性激素结合球蛋白水平升高的药物 |
| TWI359015B (en) | 1999-07-06 | 2012-03-01 | Endorech Inc | Pharmaceutical composition for treatment or preve |
| CA2386095A1 (en) * | 1999-09-30 | 2001-04-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
| FR2803750B1 (fr) * | 2000-01-17 | 2004-04-02 | Assist Publ Hopitaux De Paris | Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant |
| AU2001241779A1 (en) | 2000-02-25 | 2001-09-03 | Hollis-Eden Pharmaceuticals, Inc. | Method of treatment of prostate cancer |
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| FR2825277B1 (fr) * | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| WO2003070253A1 (en) * | 2002-02-21 | 2003-08-28 | Pantarhei Bioscience B.V. | Estrogenic component for treating decreased libido in women |
| WO2003090754A1 (en) * | 2002-04-23 | 2003-11-06 | Sahltech I Göteborg AB | Use of dhea for treatment of female hypopituitarism |
| US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| CA2496867A1 (en) * | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
| JP2008504263A (ja) * | 2004-06-23 | 2008-02-14 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
| KR20070067235A (ko) | 2004-10-20 | 2007-06-27 | 앙도르쉐르슈 인코포레이티드 | 폐경기 이후 여성의 질 건조증과 성기능 장애의 예방 및치료를 위한 성스테로이드 전구체 단독 또는 선택적인에스트로겐 수용체 조절자 및/또는 에스트로겐 및/또는타입 5 ｃＧＭＰ 포스포디에스테라제 억제제와의 배합물상태의 성스테로이드 전구체 |
| JP2008517952A (ja) * | 2004-11-01 | 2008-05-29 | アンドルシェルシュ・インコーポレイテッド | 皮膚老化となる可能性を低下させるための、または皮膚老化を処置するためのアンドロゲンの使用 |
| EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
| WO2009026473A2 (en) * | 2007-08-21 | 2009-02-26 | Hollis-Eden Pharmaceuticals, Inc. | Stabilized therapeutic compositions and formulations |
| EP2053055A1 (de) * | 2007-10-24 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | 11.beta.-Fluoro-3-acetoxyestra-3,5-dien-17-on und Verfahren zu seiner Herstellung |
| JP2010109894A (ja) * | 2008-10-31 | 2010-05-13 | Fujitsu Ltd | 弾性波フィルタ、デュープレクサ、通信モジュール、および通信装置 |
| AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| MX2012014579A (es) | 2010-06-16 | 2013-05-22 | Endorech Inc | Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos. |
| US20130178747A1 (en) * | 2012-01-10 | 2013-07-11 | Peter J. Muran | Breast cancer precursor evaluation system and proactive breast wellness program |
| CN105037532B (zh) * | 2015-07-27 | 2018-02-09 | 苏州博源医疗科技有限公司 | 17‑酮类固醇免疫原、抗体和检测试剂及制备方法 |
| CN111830169B (zh) * | 2020-07-24 | 2022-07-12 | 中山大学 | 多囊卵巢综合征诊断的化合物及应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US279982A (en) * | 1883-06-26 | Thomas beid | ||
| US424954A (en) * | 1890-04-08 | Table-knife | ||
| US816689A (en) * | 1904-07-07 | 1906-04-03 | Charles M Stevenson | Merry-go-round. |
| CH203260A (de) | 1936-11-24 | 1939-02-28 | Dreiding Boris | Mittel zur örtlichen Erzeugung von Wärme. |
| US2185187A (en) * | 1938-05-23 | 1940-01-02 | Vlieg Gerard A De | Rotary cutter |
| FR672M (enExample) * | 1960-08-31 | 1961-07-17 | ||
| US3797444A (en) | 1971-04-19 | 1974-03-19 | H Stubbs | Towing guide |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
| US4040401A (en) | 1974-11-05 | 1977-08-09 | Ethyl Corporation | Spark vacuum advance control |
| US4064654A (en) | 1975-03-20 | 1977-12-27 | H. G. Olson & Co., Inc. | Sealed closures with weather stripping |
| JPS53144014A (en) | 1977-05-20 | 1978-12-15 | Masaya Koyama | Automatic sprayer |
| DE3333240A1 (de) | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| US4634694A (en) | 1984-01-14 | 1987-01-06 | Akzo N.V. | Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives |
| US4725439A (en) | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
| US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
| US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US5155045A (en) * | 1985-01-25 | 1992-10-13 | Trustees Of The University Of Penn. | Use of male essence to alter female endocrine response |
| US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| US5887216A (en) * | 1997-03-19 | 1999-03-23 | Ricoh Company, Ltd. | Method and system to diagnos a business office device based on operating parameters set by a user |
| US5686465A (en) * | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
| US5154922A (en) | 1988-12-01 | 1992-10-13 | Schering Corporation | Compositions for transdermal delivery of estradiol |
| US5461042A (en) * | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
| AU5856090A (en) * | 1989-07-07 | 1991-02-06 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| US5641768A (en) * | 1989-11-17 | 1997-06-24 | Loria; Roger M. | 5-androstene 3β, 17β diol for treatment |
| US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
| US5506223A (en) * | 1990-08-29 | 1996-04-09 | Humanetics Corporation | Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process |
| US5183815A (en) * | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
| US5206008A (en) | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
| ZA924811B (en) * | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
| EP0627921B1 (en) * | 1992-02-24 | 2000-05-31 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| HU228385B1 (en) | 1993-01-19 | 2013-03-28 | Endorech Inc | Use of dehydroepiandrosterone for the preparation of a medicament for the treatment of sexual disordes |
| US5387583A (en) * | 1993-04-20 | 1995-02-07 | Loria; Roger M. | Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof |
| US5571933A (en) * | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
| ES2098193B1 (es) * | 1995-07-21 | 1997-12-01 | Gomez Jesus Calderon | Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea. |
| US5828688A (en) * | 1995-10-26 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission |
| US6653331B2 (en) * | 1996-07-03 | 2003-11-25 | Pharmacia & Upjohn Company | Targeted drug delivery using sulfonamide derivatives |
| US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
| US6139873A (en) * | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
| IT1292129B1 (it) * | 1997-06-11 | 1999-01-25 | Sunnimex Ltd | Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella |
| AU8779898A (en) * | 1997-08-11 | 1999-03-01 | Weider Nutrition International, Inc. | Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
| CA2306837C (en) * | 1997-10-28 | 2007-05-08 | Asivi, Llc. | Treatment of female sexual dysfunction |
| US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| TR200102867T2 (enExample) * | 1998-06-11 | 2002-06-21 | Endorecherchel@Inc | |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US6284262B1 (en) * | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| TWI359015B (en) * | 1999-07-06 | 2012-03-01 | Endorech Inc | Pharmaceutical composition for treatment or preve |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| US20030004145A1 (en) * | 2001-05-16 | 2003-01-02 | Leonard Thomas W. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
-
1999
- 1999-06-10 TR TR2001/02867T patent/TR200102867T2/xx unknown
- 1999-06-10 KR KR1020007014057A patent/KR100679735B1/ko not_active Expired - Fee Related
- 1999-06-10 CN CNB998086371A patent/CN1243550C/zh not_active Expired - Fee Related
- 1999-06-10 EP EP06018947A patent/EP1731157A3/en not_active Withdrawn
- 1999-06-10 HU HU0102483A patent/HUP0102483A3/hu unknown
- 1999-06-10 CN CNB2004100826380A patent/CN100377711C/zh not_active Expired - Fee Related
- 1999-06-10 RU RU2001101492/15A patent/RU2221569C2/ru not_active IP Right Cessation
- 1999-06-10 KR KR1020067016678A patent/KR20060098399A/ko not_active Ceased
- 1999-06-10 IL IL14022599A patent/IL140225A0/xx unknown
- 1999-06-10 PL PL99345955A patent/PL345955A1/xx not_active IP Right Cessation
- 1999-06-10 CN CNA2006100840974A patent/CN1879630A/zh active Pending
- 1999-06-10 ID IDW20010063A patent/ID27922A/id unknown
- 1999-06-10 EP EP99924625A patent/EP1083904A2/en not_active Ceased
- 1999-06-10 TR TR2001/00063T patent/TR200100063T2/xx unknown
- 1999-06-10 KR KR1020067016679A patent/KR20060098400A/ko not_active Ceased
- 1999-06-10 BR BR9911115-2A patent/BR9911115A/pt not_active Application Discontinuation
- 1999-06-10 MX MXPA00012304A patent/MXPA00012304A/es not_active Application Discontinuation
- 1999-06-10 AR ARP990102786A patent/AR018660A1/es unknown
- 1999-06-10 AU AU41274/99A patent/AU4127499A/en not_active Abandoned
- 1999-06-10 WO PCT/CA1999/000537 patent/WO1999063973A2/en not_active Ceased
- 1999-06-10 CA CA002334702A patent/CA2334702C/en not_active Expired - Fee Related
- 1999-06-10 JP JP2000553042A patent/JP2002517432A/ja active Pending
- 1999-06-10 NZ NZ536787A patent/NZ536787A/xx unknown
- 1999-06-11 TW TW095106594A patent/TWI283579B/zh not_active IP Right Cessation
- 1999-06-11 MY MYPI99002408A patent/MY131522A/en unknown
- 1999-06-11 US US09/332,356 patent/US6432940B1/en not_active Expired - Fee Related
- 1999-06-11 TW TW088109823A patent/TWI263499B/zh not_active IP Right Cessation
-
2000
- 2000-12-08 ZA ZA200007299A patent/ZA200007299B/xx unknown
- 2000-12-11 NO NO20006286A patent/NO20006286L/no not_active Application Discontinuation
-
2002
- 2002-06-10 US US10/166,506 patent/US20020187967A1/en not_active Abandoned
- 2002-06-10 US US10/166,428 patent/US20020187964A1/en not_active Abandoned
- 2002-06-10 US US10/167,727 patent/US20020187968A1/en not_active Abandoned
- 2002-06-10 US US10/166,463 patent/US6964955B2/en not_active Expired - Fee Related
- 2002-06-10 US US10/166,505 patent/US20020187966A1/en not_active Abandoned
- 2002-06-10 US US10/170,083 patent/US20020187970A1/en not_active Abandoned
- 2002-06-10 US US10/166,427 patent/US6995150B2/en not_active Expired - Fee Related
- 2002-06-10 US US10/167,729 patent/US20020187969A1/en not_active Abandoned
- 2002-06-10 US US10/166,423 patent/US20020187973A1/en not_active Abandoned
- 2002-06-10 US US10/166,424 patent/US6884795B2/en not_active Expired - Fee Related
-
2006
- 2006-05-17 IL IL175723A patent/IL175723A0/en unknown
-
2007
- 2007-04-11 US US11/734,165 patent/US20080161277A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ536787A (en) | Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol | |
| RU2001101492A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНДРОСТ-5-EH-3-β, 17β-ДИОЛ, И ЕГО ИСПОЛЬЗОВАНИЕ | |
| NZ250712A (en) | Using dehydroepiandrosterone (dhea), its sulphate (dhea-s), or compounds convertible thereto for contraception, treating menopausal symptoms or cosmetic imbalances of sex steroids | |
| CA2467222A1 (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
| DE2817157A1 (de) | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie | |
| MX2009005307A (es) | Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide. | |
| HK1048761A1 (zh) | 结合雌激素的选择性雌激素受体调节剂 | |
| NZ502449A (en) | Tricyclic vasopressin agonists and their pharmaceutical use | |
| IL158903A0 (en) | Use of sulodexide for the treatment of inflammatory bowel disease | |
| IL158281A0 (en) | A jasmonate pharmaceutical composition for treatment of cancer | |
| AR073972A2 (es) | Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas | |
| BRPI0400214A8 (pt) | Composições e aplicações farmacêuticas para a obtenção confiável de níveis aceitáveis de testosterona no soro | |
| ATE363487T1 (de) | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene | |
| WO2001003687A3 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
| US20060063723A1 (en) | Pharmaceutical composition comprising esterol derivatives for use in cancer therapy | |
| HRP20030387A2 (en) | Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases | |
| Robben et al. | Effects of intestinal microbial bile salt sulfatase activity on bile salt kinetics in gnotobiotic rats | |
| HUP0500346A2 (hu) | Konjugált ösztrogének alkalmazása ösztrogénpótó terápiában hatásos gyógyszerkészítmények előállítására | |
| EP1219288A3 (en) | Treatment for skin | |
| DE60017281D1 (de) | Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung | |
| WO2004105768A8 (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
| Elger et al. | Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions | |
| US20010056087A1 (en) | Use of 5alpha-androst-1en-3,17-diol to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | |
| WO2004093852A3 (en) | Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders | |
| WO2001003774A3 (en) | Pharmaceutical composition for the treatment of calcification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |